Evidence map›Paper›PMID 40337587›Full record

ArticleCureus2025

Idiopathic Granulomatous Mastitis: Is It Still a Mysterious Entity?

Lamees Yaghan, Abdulla I Mohamed, Rami Yaghan

Abstract readEditorial
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Lamees YaghanMedical Skills and Simulation Center, Arabian Gulf University, Manama, BHR.
Abdulla I MohamedDepartment of Surgery, Arabian Gulf University, Manama, BHR.
Rami YaghanDepartment of Surgery, Arabian Gulf University, Manama, BHR.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Idiopathic granulomatous mastitis (IGM) is stereotypically described as a rare, mysterious breast disorder that is difficult to diagnose and treat. Initial literature about IGM consisted of case reports and retrospective case series. Understandably, this led to arbitrary, and occasionally contradictory, surgical and medical treatment approaches. Over the last two decades, IGM has markedly departed from its classical description. It is no longer that rare disease and the spectrum of clinical presentation has widely expanded, both locally and systematically. In addition, a relatively good number of recent multicenter, meta-analysis, systematic reviews, and consensus reports about IGM have become available. The advancements in the diagnostic techniques of IGM and the growing knowledge about IGM treatment options no longer justify the routine labeling of IGM as a mysterious entity. The preponderance of evidence is now in support of complementary, rather than contradictory, surgical and systemic immunosuppressive treatment. Patients with IGM are better treated under the care of a multidisciplinary team. This will facilitate personalizing the treatment according to the needs of each patient with the minimum possible morbidity. There is a need for a comprehensive classification system for IGM that reflects the clinical variants, the radiological patterns, and the pathological details of IGM. Such a classification will provide useful hints about the treatment, the likelihood of the recurrence, and the expected natural history of IGM.

Indexed as

classificationgranulomatous lobular mastitisidiopathic granulomatous mastitismultidisciplinary teamtreatment

Identifiers

PMID40337587
PMCPMC12056568

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.